|drug343||Azithromycin and hydroxychloroquine Wiki||1.00|
There is one clinical trial.
The use of both levamisole & Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection
Description: Improvement of fever in degrees celsiusMeasure: COVID 19 induced fever in both groups Time: 4 weeks
Description: improvement of dyspnea by normalization of respiratory rateMeasure: COVID 19 induced dyspnea in both groups Time: 4 weeks
Description: PCR of COVID 19 changes from positive to negativeMeasure: COVID 19 viral load in both groups Time: 4 weeks
Description: CRP in mg/dLMeasure: laboratory clearance in both groups: CRP in mg/dL Time: 4 weeks
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports